Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

May 13, 2008

GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech)

Analysis of: Glaxo Tests Tykerb vs Herceptin in Early Cancer | www.therapeuticsdaily.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CCKenneth Algazy, MD 
Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Implications: Glaxo is trying to move Tykerb ahead of Herceptin in a first line/neoajuvant/adjuvant setting in Her2Neu + Breast cancer.

Analysis: Logical but risky. If it loses it will be no worse off than where it is placed now, but if it wins the sky is the limit in Her2Neu + breast cancer. My guess?? No idea, but the oral Tykerb would be appreciated by patients but not oncologists who will make no profit from an oral agent.


Report a Concern

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics